MYDA Advisors LLC Has $34,000 Stock Position in Agilon Health, Inc. $AGL

MYDA Advisors LLC lowered its stake in Agilon Health, Inc. (NYSE:AGL) by 58.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after selling 70,000 shares during the quarter. MYDA Advisors LLC’s holdings in Agilon Health were worth $34,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in AGL. Wealthcare Advisory Partners LLC acquired a new position in shares of Agilon Health in the 3rd quarter valued at $26,000. LPL Financial LLC lifted its stake in shares of Agilon Health by 213.4% in the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock valued at $30,000 after purchasing an additional 30,000 shares during the period. Krilogy Financial LLC acquired a new position in shares of Agilon Health in the 4th quarter valued at $34,000. CIBC Bancorp USA Inc. acquired a new position in shares of Agilon Health in the 3rd quarter valued at $34,000. Finally, Merit Financial Group LLC acquired a new position in shares of Agilon Health in the 4th quarter valued at $35,000.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AGL. Barclays raised Agilon Health from an “underweight” rating to an “equal weight” rating and set a $81.00 price target on the stock in a research note on Tuesday, May 26th. Wells Fargo & Company reissued an “overweight” rating and issued a $72.00 price target (up from $37.50) on shares of Agilon Health in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised Agilon Health from a “hold” rating to a “buy” rating and increased their price target for the company from $33.00 to $49.00 in a research note on Thursday, May 7th. Citigroup restated a “neutral” rating and issued a $80.00 price objective (up from $18.75) on shares of Agilon Health in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Agilon Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Agilon Health currently has an average rating of “Hold” and a consensus target price of $58.73.

Agilon Health Price Performance

AGL opened at $113.19 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.08. Agilon Health, Inc. has a 12 month low of $7.48 and a 12 month high of $118.25. The company has a fifty day simple moving average of $61.29 and a 200 day simple moving average of $32.15. The stock has a market cap of $1.89 billion, a P/E ratio of -5.25 and a beta of 3.02.

Agilon Health (NYSE:AGL) last released its quarterly earnings data on Wednesday, May 6th. The company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.76. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. The business had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. On average, research analysts expect that Agilon Health, Inc. will post -3.5 EPS for the current year.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.